A Policy Statement on Cannabis Rescheduling in The Pharmacologist
SSDP Ambassador and former chair of SSDP’s Science Policy Committee, Elijah Ullman, PhD, co-authored the Cover Story of the August edition of The Pharmacologist focused on Cannabis Rescheduling as part of the ASPET (American Society for
Pharmacology and Experimental Therapeutics) Drug Research Policy Subcommittee.
The policy statement discusses how drug scheduling can also create a regulatory burden that negatively impacts research, especially when the research involves schedule-I drugs.
SSDP continues the fight against research harm after taking the DEA to court last year over scheduling two less-known psychedelic compounds, DOI and DOC to Schedule I. This cover story references our DOI/DOC hearing on page 22.
The recommendation of the ASPET Science Policy Committee Drug Research Policy Subcommittee states,
By supporting the rescheduling of cannabis from schedule I to III, the membership of ASPET recommends the reduction of the current federal prohibitions to cannabis research and facilitating the continued investigation into its use as a medicinal substance.
